Qiagen (NYSE:QGEN) Shares Purchased by Private Advisor Group LLC

Private Advisor Group LLC increased its position in shares of Qiagen (NYSE:QGEN) by 8.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,251 shares of the company’s stock after acquiring an additional 461 shares during the quarter. Private Advisor Group LLC’s holdings in Qiagen were worth $285,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of QGEN. US Bancorp DE raised its stake in Qiagen by 124.4% during the first quarter. US Bancorp DE now owns 75,529 shares of the company’s stock worth $3,247,000 after purchasing an additional 41,868 shares during the period. TD Asset Management Inc purchased a new position in Qiagen during the second quarter worth approximately $2,103,000. Edgestream Partners L.P. purchased a new position in Qiagen during the first quarter worth approximately $1,492,000. Susquehanna International Securities Ltd. purchased a new position in Qiagen during the first quarter worth approximately $5,731,000. Finally, Forsta AP Fonden purchased a new position in Qiagen during the first quarter worth approximately $834,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on QGEN. Robert W. Baird increased their price target on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Qiagen presently has an average rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Stock Performance

Qiagen stock opened at $43.87 on Thursday. Qiagen has a 12-month low of $37.51 and a 12-month high of $47.44. The company has a market capitalization of $10.01 billion, a price-to-earnings ratio of 145.98, a price-to-earnings-growth ratio of 3.33 and a beta of 0.41. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. The firm’s fifty day moving average price is $44.11 and its 200 day moving average price is $43.70.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.